Ca2+ antagonist-insensitive coronary smooth muscle contraction involves activation of ε-protein kinase C-dependent pathway

American Journal of Physiology - Cell Physiology

Volumn 285, Issue 6 54-6, 2003, Pages

  Dallas, Andrea ^b   Khalil, Raouf A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

Calcium; Eicosanoids; Vascular smooth muscle

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; ARACHIDIC ACID; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CALPHOSTIN C; DILTIAZEM; FURA 2; INHIBITOR PROTEIN; PROSTAGLANDIN F2 ALPHA; PROTEIN KINASE C; PROTEIN KINASE C EPSILON V1; PROTEIN KINASE C EPSILON V2; PROTEIN KINASE C INHIBITOR; UNCLASSIFIED DRUG; VERAPAMIL; CALCIUM; ENZYME INHIBITOR; PROTEIN KINASE C EPSILON; VASOCONSTRICTOR AGENT;

ANGINA PECTORIS; ANIMAL CELL; ANTIBODY SPECIFICITY; ARTICLE; CALCIUM ANTAGONISM; CALCIUM CELL LEVEL; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DISEASE; CYTOSOL; ENZYME ACTIVATION; MALE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTION; SWINE; VASCULAR SMOOTH MUSCLE; ANIMAL; CELL CULTURE; CHEMISTRY; CORONARY ARTERY SPASM; CORONARY BLOOD VESSEL; CYTOLOGY; DRUG EFFECT; IMMUNOBLOTTING; INTRACELLULAR FLUID; METABOLISM; MUSCLE CONTRACTION; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN TRANSPORT; VASOCONSTRICTION;

ANIMALIA; SUIDAE; SUS SCROFA;

ANIMALS; CALCIUM; CALCIUM CHANNEL BLOCKERS; CELLS, CULTURED; CORONARY VASOSPASM; CORONARY VESSELS; DINOPROST; ENZYME ACTIVATION; ENZYME INHIBITORS; IMMUNOBLOTTING; INTRACELLULAR FLUID; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; PROTEIN KINASE C; PROTEIN KINASE C-EPSILON; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; SWINE; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 0242678496     PISSN: 03636143     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpcell.00066.2003     Document Type: Article

References (42)

1. Baird MG, Juneau M, Nadeau C, Clermont P, Chin C, and Boulet AA. Efficacy and safety of evening administration of controlled-delivery diltiazem capsules in chronic stable angina patients. Am J Ther 2: 401-406, 1995.
2. Brogden RN and Benfield P. Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease. Drugs 51: 792-819, 1996.
3. Cannon PJ. Eicosanoids and the blood vessel wall. Circulation 70: 523-528, 1984.
4. 2+-induced contraction of cat esophageal circular smooth muscle cells. Am J Physiol Cell Physiol 280: C980-C992, 2001.
5. Chen L, Hahn H, Wu G, Chen CH, Liron T, Schechtman D, Cavallaro G, Banci L, Guo Y, Bolli R, Dorn GW 2nd, and Mochly-Rosen D. Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and epsilon PKC. Proc Natl Acad Sci USA 98: 1114-11119, 2001.
6. Chen L, Wright LR, Chen CH, Oliver SF, Wender PA, and Mochly-Rosen D. Molecular transporters for peptides: delivery of a cardioprotective epsilonPKC agonist peptide into cells and intact ischemic heart using a transport system, R(7). Chem Biol 8: 1123-1129, 2001.
7. Dubyak GR and Kertesy SB. Inhibition of GTPγS-dependent phospholipase D and Rho membrane association by calphostin is independent of protein kinase C catalytic activity. Arch Biochem Biophys 341: 129-139, 1997.
8. Fuster V, Badimon L, Badimon JJ, and Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 326: 310-318, 1992.
9. Gratton JP, Yu J, Griffith JW, Babbitt RW, Scotland RS, Hickey R, Giordano FJ, and Sessa WC. Cell-permeable peptides improve cellular uptake and therapeutic gene delivery of replication-deficient viruses in cells and in vivo. Nat Med 9: 357-363, 2003.
10. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 260: 3440-3450, 1985.
11. Hempel A, Maasch C, Heintze U, Lindschau C, Dietz R, Luft FC, and Haller H. High glucose concentrations increase endothelial cell permeability via activation of protein kinase C alpha. Circ Res 81: 363-371, 1997.
12. Horowitz A, Menice CB, Laporte R, and Morgan KG. Mechanisms of smooth muscle contraction. Physiol Rev 76: 967-1003, 1996.
13. Jespersen CM. Verapamil in acute myocardial infarction. The rationales of the VAMI and DAVIT III trials. Cardiovasc Drugs Ther 14: 99-105, 2000.
14. Jiang MJ and Morgan KG. Intracellular calcium levels in phorbol ester-induced contractions of vascular muscle. Am J Physiol Heart Circ Physiol 253: H1365-H1371, 1987.
15. 2α during repeated downregulation of ε-protein kinase C. J Cardiovasc Pharmacol 35: 491-501, 2000.
16. 2+ entry during coronary artery contraction by vasoactive eicosanoids. Can J Physiol Pharmacol 76: 1110-1119, 1998.
17. Kanashiro CA and Khalil RA. Signal transduction by protein kinase C in mammalian cells. Clin Exp Pharmacol Physiol 25: 974-985, 1998.
18. Kawano H, Fujii H, Motoyama T, Kugiyama K, Ogawa H, and Yasue H. Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography. Am J Cardiol 85: 26-30, 2000.
19. i threshold for translocation of the α-protein kinase C isoform. Am J Physiol Cell Physiol 266: C1544-C1551, 1994.
20. 2+-independent isoforms of protein kinase C differentially translocate in smooth muscle. Am J Physiol Cell Physiol 263: C714-C719, 1992.
21. Khalil RA and Morgan KG. Phenylephrine-induced translocation of protein kinase C and shortening of two types of vascular cells of the ferret. J Physiol 455: 585-599, 1992.
22. Khalil RA and van Breemen C. Sustained contraction of vascular smooth muscle: calcium influx or C-kinase activation? J Pharmacol Exp Ther 244: 537-542, 1988.
23. Khalil RA and van Breemen C. Mechanisms of calcium mobilization and homeostasis in vascular smooth muscle and their relevance to hypertension. In: Hypertension: Pathophysiology, Diagnosis, and Management, edited by Laragh JH and Brenner BM. New York: Raven, 1995, p. 523-540.
24. 2α generation from acute myocardial infarction heart: insight into abrupt reperfusion and oxidant stress. Prostaglandins Leukot Essent Fatty Acids 64: 161-166, 2001.
25. Kobayashi E, Nakano H, Morimoto M, and Tamaoki T. Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun 159: 548-553, 1989.
26. Kumar A, Chandna H, Santhanam V, and Denes P. Refractory vasospasm with a malignant course. Clin Cardiol 23: 127-130, 2000.
27. Liou YM and Morgan KG. Redistribution of protein kinase C isoforms in association with vascular hypertrophy of rat aorta. Am J Physiol Cell Physiol 267: C980-C989, 1994.
28. Martiny-Baron G, Kazanietz MG, Mischak H, Blumberg PM, Kochs G, Hug H, Marme D, and Schachtele C. Selective inhibition of protein kinase C isozymes by the indolocarbazole Go6976. J Biol Chem 268: 9194-9197, 1993.
29. Mehrabi MR, Serbecic N, Ekmekcioglu C, Tamaddon F, Wild T, Plesch K, Sinzinger H, and Glogar HD. Enhanced accumulation of the isoprostane, 8-epi-PGF2alpha, in human aortic and pulmonary valves of patients with coronary heart disease. Histol Histopathol 17: 1053-1059, 2002.
30. i during inhibition of coronary smooth muscle contraction by 17β-estradiol, progesterone, and testosterone. J Pharmacol Exp Ther 291: 44-52, 1999.
31. i in vascular smooth muscle cells of female rat. Am J Physiol Cell Physiol 278: C834-C844, 2000.
32. Nayler WG, Perry SE, Elz JS, and Daly MJ. Calcium, sodium, and the calcium paradox. Circ Res 55: 227-237, 1984.
33. 2 on coronary flow and myocardial function. Am J Physiol Heart Circ Physiol 255: H153-H159, 1988.
34. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258: 607-614, 1992.
35. Opie LH. Mechanisms whereby calcium channel antagonists may protect patients with coronary artery disease. Eur Heart J 18 Suppl A: A92-A104, 1997.
36. 2+] determines myosin phosphorylation in agonist-stimulated swine arterial smooth muscle. Circ Res 63: 593-603, 1988.
37. Rigel DF and Shetty SS. A novel model of conduit coronary constriction reveals local actions of endothelin-1 and prostaglandin F2α. Am J Physiol Heart Circ Physiol 272: H2054-H2064, 1997.
38. Silvestry FE and Kimmel SE. Calcium-channel blockers in ischemic heart disease. Curr Opin Cardiol 11: 434-439, 1996.
39. Spitaler M, Villunger A, Grunicke H, and Uberall F. Unique structural and functional properties of the ATP-binding domain of atypical protein kinase C-iota. J Biol Chem 275: 33289-33296, 2000.
40. Togashi H, Hirshman CA, and Emala CW. Qualitative immunoblot analysis of PKC isoforms expressed in airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 272: L603-L607, 1997.
41. Toullec D, Pianetti P, Coste H, Bellevergue P, Grand-Perret T, Ajakane M, Baudet V, Boissin P, Boursier E, Loriolle F, Duhamel L, Charon D, and Kirilovsky J. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem 266: 15771-15781, 1991.
42. Xuan YT, Guo Y, Zhu Y, Han H, Langenbach R, Dawn B, and Bolli R. Mechanism of cyclooxygenase-2 upregulation in late preconditioning. J Mol Cell Cardiol 35: 525-537, 2003.